Takeda Quarterly Financial Report for the Quarter Ended June 30, 2022

On July 28, 2022 Takeda reported its second quarter 2022 results (Presentation, Takeda, JUL 28, 2022, View Source [SID1234617152]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


10-Q – Quarterly report [Sections 13 or 15(d)]

Seagen has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Novavax CEO Appointed to U.S.-India CEO Forum

On July 28, 2022 Novavax reported that Stanley C. Erck, President and Chief Executive Officer, Novavax, has been appointed by U.S. Secretary of Commerce Gina Raimondo to the U.S.-India CEO Forum (Forum) which brings together top-level business executives to discuss ways to strengthen the economic and commercial ties between the two countries, and to communicate their joint recommendations to the U.S. and Indian governments (Press release, Novavax, JUL 28, 2022, View Source [SID1234617143]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This appointment will provide Novavax’ CEO with the opportunity to lend insights based on his background of working extensively with some of India’s top business leaders. Further, Novavax will be a contributing partner in strengthening U.S. relationships with leaders in India and in a wide range of industries.

Established in 2005, the U.S.-India CEO Forum also informs government-to-government discussions, such as the U.S.-India Commercial Dialogue, on commercial affairs and highlights the strategic importance of the bilateral relationship.

Sangamo Therapeutics Announces Second Quarter 2022 Conference Call and Webcast

On July 28, 2022 Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, reported that the company has scheduled the release of its second quarter 2022 financial results after the market closes on Thursday, August 4, 2022 (Press release, Sangamo Therapeutics, JUL 28, 2022, View Source [SID1234617142]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The press release will be followed by a conference call at 4:30 p.m. ET, which will be open to the public. During the conference call, the company will review its financial results and provide business updates.

Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided, or to use the dial-out option to connect their phone instantly. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations.

A replay will be available following the conference call, accessible under Events and Presentations.

Invitation to MorphoSys’ Second Quarter and First Half Year 2022 Results Conference Call on August 4, 2022

On July 28, 2022 MorphoSys AG (FSE: MOR; NASDAQ: MOR) reported that it will publish its results for the second quarter and first half year 2022 results on August 3, 2022 at 10:00 pm CEST (9:00 pm BST; 4:00 pm EDT) (Press release, MorphoSys, JUL 28, 2022, View Source [SID1234617138]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MorphoSys’ Management team will host a conference call and webcast on August 4, 2022 at 2:00 pm CEST (1:00 pm BST; 8:00 am EDT) to present the second quarter and first half year financial results 2022 and provide an outlook for 2022.
The conference call will start with a presentation by the Management team followed by a Q&A session.
A live webcast and slides will be made available at the Investors section on MorphoSys’ website, www.morphosys.com.

Please dial in 10 minutes before the beginning of the conference.
A replay of the conference will also be available at the corporate website following the live event.